Tags

Type your tag names separated by a space and hit enter

The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus.
Am J Cardiovasc Drugs. 2009; 9(5):283-91.AJ

Abstract

Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk. A number of interventional trials have shown that these patients benefit greatly from aggressive BP lowering, especially when the drug regimen comprises an inhibitor of the renin-angiotensin system. The results of the placebo-controlled ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) trial, conducted in patients with type 2 diabetes, are exemplary in this respect. The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. The beneficial effects were obtained regardless of baseline BP and whether or not the patients were receiving antihypertensive therapy.

Authors+Show Affiliations

Division of Clinical Pathophysiology, University Hospital and University of Lausanne, Lausanne, Switzerland. Bernard.Waeber@chuv.chNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19791837

Citation

Waeber, Bernard, et al. "The ADVANCE Trial: Clarifying the Role of Perindopril/indapamide Fixed-dose Combination in the Reduction of Cardiovascular and Renal Events in Patients With Diabetes Mellitus." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 9, no. 5, 2009, pp. 283-91.
Waeber B, de la Sierra A, Ruilope LM. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2009;9(5):283-91.
Waeber, B., de la Sierra, A., & Ruilope, L. M. (2009). The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, 9(5), 283-91. https://doi.org/10.2165/10061600-000000000-00000
Waeber B, de la Sierra A, Ruilope LM. The ADVANCE Trial: Clarifying the Role of Perindopril/indapamide Fixed-dose Combination in the Reduction of Cardiovascular and Renal Events in Patients With Diabetes Mellitus. Am J Cardiovasc Drugs. 2009;9(5):283-91. PubMed PMID: 19791837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. AU - Waeber,Bernard, AU - de la Sierra,Alejandro, AU - Ruilope,Luis M, PY - 2009/10/2/entrez PY - 2009/10/2/pubmed PY - 2010/1/20/medline SP - 283 EP - 91 JF - American journal of cardiovascular drugs : drugs, devices, and other interventions JO - Am J Cardiovasc Drugs VL - 9 IS - 5 N2 - Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk. A number of interventional trials have shown that these patients benefit greatly from aggressive BP lowering, especially when the drug regimen comprises an inhibitor of the renin-angiotensin system. The results of the placebo-controlled ADVANCE (Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) trial, conducted in patients with type 2 diabetes, are exemplary in this respect. The systematic use of a fixed-dose combination containing the ACE inhibitor perindopril and the diuretic indapamide afforded substantial protection against cardiovascular mortality and myocardial infarction, while providing important renoprotection, reducing the development of micro- and macroalbuminuria, and allowing regression of nephropathy. The beneficial effects were obtained regardless of baseline BP and whether or not the patients were receiving antihypertensive therapy. SN - 1175-3277 UR - https://www.unboundmedicine.com/medline/citation/19791837/The_ADVANCE_trial:_clarifying_the_role_of_perindopril/indapamide_fixed_dose_combination_in_the_reduction_of_cardiovascular_and_renal_events_in_patients_with_diabetes_mellitus_ L2 - https://dx.doi.org/10.2165/10061600-000000000-00000 DB - PRIME DP - Unbound Medicine ER -